Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology - Tập 7 - Trang 198-207 - 2003
Tóm tắt
Background: Phase I and Phase II studies in patients with moderate to severe plaque psoriasis demonstrated that intravenous (IV) efalizumab improved clinical signs and symptoms and was well tolerated. Objective: To determine if subcutaneous (SC) delivery of efalizumab improves chronic plaque psoriasis and demonstrates an acceptable safety profile. Methods: This was a Phase I, open-label, single- and multiple-dose, escalating-dose study. Subjects received a single dose of efalizumab (0.3 mg/kg/wk SC) or escalating multiple doses of efalizumab (0.50–2.0 mg/kg/wk SC). Effectiveness was assessed using the Psoriasis Area and Severity Index (PASI), target lesion assessment, and Physician’s Global Assessment (PGA). Safety was assessed by evaluating adverse events, clinical laboratory test results, physical examination results, immunologic responses, and vital signs. Results: PASI score, target lesion assessment, and PGA showed improvement of approximately 40%–60% in signs and symptoms of plaque psoriasis by day 56. Mean PASI scores were still declining at the end of the eight-week dosing period, suggesting that longer duration of treatment would be more effective. By day 91, mean PASI scores were 16.2 vs. 14.6 at day 56 in the 0.5–1.0-mg/kg/wk group and 11.7 vs. 10.1 in the 1.0–2.0-mg/kg/wk group. This demonstrates that, on average, patients maintained their treatment benefit during the 42-day followup period. Overall, there were considerably fewer adverse events than in previous IV studies. These consisted principally of mild to moderate headache, pain, and rhinitis. No allergic reactions were observed. Antibodies to efalizumab were observed in only one subject (2%) and did not have any clinical relevance. Conclusion: The SC administration of eight weekly doses of efalizumab improves signs and symptoms of psoriasis. The treatment was safe and very well tolerated. In comparison to previously published results with IV efalizumab, SC administration of efalizumab improves overall safety and tolerability, with the additional advantage of greater convenience.
Tài liệu tham khảo
SL Gottlieb P Gilleaudeau R Johnson et al. (1995) ArticleTitleResponse of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1 442–447 Occurrence Handle1:CAS:528:DyaK2MXls1SgtLw%3D Occurrence Handle7585092
JD Bos MM Meinardi T van Joost et al. (1989) ArticleTitleUse of cyclosporin in psoriasis. Lancet 2 1500–1502 Occurrence Handle10.1016/S0140-6736(89)92941-3 Occurrence Handle1:STN:280:By%2BD1MjjvFQ%3D Occurrence Handle2574777
CN Ellis MS Fradin JM Messana et al. (1991) ArticleTitleCyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324 277–284 Occurrence Handle1:STN:280:By6D1Mvps1I%3D Occurrence Handle1986287
AB Gottlieb B Lifshitz SM Fu et al. (1988) ArticleTitleExpression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 164 1013–1028
TA Springer (1994) ArticleTitleTraffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 301–314 Occurrence Handle1:CAS:528:DyaK2cXhs1Srtrg%3D Occurrence Handle7507411
LM Bradley SR Watson (1996) ArticleTitleLymphocyte migration into tissue: the paradigm derived from CD4 subsets. Curr Opin Immunol 8 312–320 Occurrence Handle10.1016/S0952-7915(96)80118-X Occurrence Handle1:CAS:528:DyaK28Xktlegtr4%3D Occurrence Handle8793991
A Grakoui SK Bromley C Sumen et al. (1999) ArticleTitleThe immunological synapse: a molecular machine controlling T cell activation. Science 285 221–227 Occurrence Handle10.1126/science.285.5425.221 Occurrence Handle1:CAS:528:DyaK1MXks1SjsLg%3D Occurrence Handle10398592
T Collins (1995) ArticleTitleAdhesion molecules in leukocyte emigration. Sci Am Sci Med 28–37
ML Dustin R Rothlein AK Bhan et al. (1986) ArticleTitleInduction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137 245–254 Occurrence Handle1:CAS:528:DyaL28XksVSqs74%3D Occurrence Handle3086451
BJ Nickoloff CE Griffiths JN Barker (1990) ArticleTitleThe role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease–-1990 update. J Invest Dermatol 94 151S–157S Occurrence Handle1:STN:280:By%2BB2sfhsVA%3D Occurrence Handle2191050
M Zeigler Y Chi DB Tumas et al. (2001) ArticleTitleAnti-CD11a ameliorates disease in the human psoriatic skin–SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 81 1253–1261 Occurrence Handle1:CAS:528:DC%2BD3MXnt1Snt78%3D Occurrence Handle11555673
JP Arm TH Lee (1992) ArticleTitleThe pathobiology of bronchial asthma. Adv Immunol 51 323–382 Occurrence Handle1:CAS:528:DyaK3sXnvVSjsA%3D%3D Occurrence Handle1502977
TT Kung H Jones GK Adams et al. (1994) ArticleTitleCharacterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 105 83–90 Occurrence Handle1:STN:280:ByuA2s3mt1Q%3D Occurrence Handle8086833
U Herz U Lumpp JC Da Palma et al. (1996) ArticleTitleThe relevance of murine animal models to study the development of allergic bronchial asthma. Immunol Cell Biol 74 209–217 Occurrence Handle1:STN:280:BymA3MrntVQ%3D Occurrence Handle8724012
RP Warren JS Lofgreen D Steinmuller (1973) ArticleTitleDifferential survival of heart and skin allografts in inbred rats. Transplant Proc 5 717–719 Occurrence Handle1:STN:280:CSyC2M3mtVQ%3D Occurrence Handle4572131
DK Trager BA Banks GE Rosenbaum et al. (1989) ArticleTitleCardiac allograft prolongation in mice treated with combined posttransplantation total-lymphoid irradiation and anti-L3T4 antibody therapy. Transplantation 47 587–591 Occurrence Handle1:STN:280:BiaB3czptlE%3D Occurrence Handle2523098
EK Nakakura RA Shorthouse B Zheng et al. (1996) ArticleTitleLong-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation 62 547–552 Occurrence Handle10.1097/00007890-199609150-00001 Occurrence Handle1:CAS:528:DyaK28Xmtlylu78%3D Occurrence Handle8830813
RS Poston RC Robbins B Chan et al. (2000) ArticleTitleEffects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation 69 2005–2013 Occurrence Handle10.1097/00007890-200005270-00006 Occurrence Handle1:CAS:528:DC%2BD3cXksF2rt7c%3D Occurrence Handle10852588
M Nishihara M Gotoh T Fukuzaki et al. (1995) ArticleTitlePotent immunosuppressive effect of anti-LFA-1 monoclonal antibody on islet allograft rejection. Transplant Proc 27 372 Occurrence Handle1:STN:280:ByqC1cvms1c%3D Occurrence Handle7879025
WA Werther TN Gonzalez SJ O’Connor et al. (1996) ArticleTitleHumanization of an antilymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157 4986–4995 Occurrence Handle1:CAS:528:DyaK28Xnt1Gmtbk%3D Occurrence Handle8943405
K Papp R Bissonnette JG Krueger et al. (2001) ArticleTitleThe treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45 665–674 Occurrence Handle10.1067/mjd.2001.117850 Occurrence Handle1:STN:280:DC%2BD3Mnms1ejuw%3D%3D Occurrence Handle11606914
A Gottlieb JG Krueger R Bright et al. (2000) ArticleTitleEffects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 42 428–435 Occurrence Handle1:STN:280:DC%2BD3c7ltlGluw%3D%3D Occurrence Handle10688712
AB Gottlieb JG Krueger K Wittkowski et al. (2002) ArticleTitlePsoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138 591–600 Occurrence Handle1:CAS:528:DC%2BD38Xkt12rsrk%3D Occurrence Handle12020219
RJ Bauer RL Dedrick ML White et al. (1999) ArticleTitlePopulation pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27 397–420 Occurrence Handle10.1023/A:1020917122093 Occurrence Handle1:CAS:528:DC%2BD3cXjtFSntb8%3D Occurrence Handle10826130
T Fredriksson U Pettersson (1978) ArticleTitleSevere psoriasis–-oral therapy with a new retinoid. Dermatologica 157 238–244 Occurrence Handle357213